BERLIN, Germany, Dec 16, 2025 - (ACN Newswire via SeaPRwire.com) - Market Logic Software, the market-leading SaaS provider of insight management solutions, has announced a partnership with Matter, a New Zealand-based intelligence company for brand builders and experience creators. This collaboration marks an exciting step in Market Logic's expansion across APAC, particularly in New Zealand and Australia, where Matter is working closely with local brands that want to deepen their customer and market understanding.Together, Market Logic and Matter will empower APAC businesses to uncover unique insights faster and take swifter action. By combining the power of Market Logic's AI-powered insights platform, DeepSights, with the data, research and measurement expertise of Matter, the two companies will help ambitious local brands drive international growth through intelligence."New Zealand and Australia are home to exceptional brands who are no strangers to innovation and creativity," said Oliver Allen. "By combining our strategic and creative intelligence with DeepSights' market leading AI capabilities, we're helping these teams accelerate confident decision-making. We believe the real magic happens when smart, industry leading technology is combined with deep research, cultural and insights expertise, and that's what we hope to deliver through this partnership.""Matter understands the unique dynamics of APAC brands and the consumers they serve," said Maarten Sambre, SVP Global Sales at Market Logic Software. "With DeepSights, we can support these organisations with verified insights at speed, while Matter ensures those insights translate into smart, creative brand and experience strategies."This partnership also represents a shared commitment to supporting APAC's rapidly evolving insights landscape, where the demand for AI-powered intelligence continues to accelerate. Market Logic and Matter will collaborate on brand engagements, regional activation campaigns, and thought leadership focused on smarter, insight-led decision making.For more information about the partnership, please contact:Daniela ZuinCMOMarket Logic Softwaredaniela.zuin@marketlogicsoftware.comTel: +44 7799 113040Oliver AllenPartnerMatteroliver.allen@matter.nzTel: +64 27 448 6008About Market Logic SoftwareMarket Logic is the leading SaaS provider of market intelligence and insights solutions. Powered by our special purpose AI for Insights technology DeepSights, our platform allows insights teams and business decisions makers to turn trusted insights into business impact at scale and speed. We've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic. Find out more at https://marketlogicsoftware.com/.About MatterMatter is an intelligence company for brand builders and experience creators. We help organisations gain the clarity and confidence they need to make decisions that unleash commercial success. Blending strategic rigour with creative craft, we transform complex data into simple, powerful intelligence that drives brand and experience performance. Clients-from ambitious startups to global enterprises-choose Matter for our ability to deliver fast, impactful, and beautifully executed work.Find out more at https://www.matter.nz/SOURCE: Market Logic Software, GmbH Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
KUALA LUMPUR, December 16, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the "Company" or "CBL"), the listing vehicle of the Banle Group ("Banle" or "the Group") is proud to announce it has been awarded the prestigious EcoVadis Silver Medal, placing the company among the top 15% of organizations globally assessed for sustainability performance.The EcoVadis Silver Medal recognizes CBL's robust sustainability management system and comprehensive approach to corporate responsibility across four key dimensions: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. This achievement reflects the company's commitment to integrating sustainability into its core business operations and value chain."Earning the EcoVadis Silver Medal is a significant milestone that validates our ongoing dedication to responsible business practices," said Dr. Teck Lim Chia, Chairman and CEO of Banle Group. "At CBL, sustainability isn't an add-on—it's embedded in how we operate daily. This recognition reflects our team's collective efforts to build a business that delivers both commercial success and positive societal impact."The EcoVadis assessment, which analyzes companies' sustainability management systems based on international standards including the UN Global Compact, ISO 26000, and ILO conventions, places CBL in the 85th percentile or higher globally. To qualify for the Silver Medal, CBL demonstrated strong performance across all sustainability themes, meeting rigorous minimum score requirements in each category.This achievement comes as CBL continues to advance its sustainability initiatives, including its commitment to maritime decarbonization through biofuel distribution and next-generation fuel development. The company has recently reported a 154.7% year-on-year surge in biofuel sales in the first half of 2025, demonstrating how environmental stewardship and business growth can go hand in hand.CBL's sustainability journey includes measurable carbon reduction targets, ethical supply chain governance, community investment programs, and transparent ESG reporting. The company's recent recognition with the "Excellent Sustainability Award" at the CGMA Annual Awards 2025 and "Directors of the Year Awards – Listed Companies Executive Directors category - Dr. Teck Lim Chia" presented by the Hong Kong Institute of Directors (HKIoD) further underscores its leadership position in sustainable maritime logistics.The company remains committed to advancing its sustainability performance, with plans to further strengthen its environmental initiatives, enhance social impact programs, and deepen governance frameworks in alignment with global best practices. Caption: CBL INTERNATIONAL LTD has been awarded the EcoVadis Silver Medal, a recognition granted to the top 15% of organizations globally assessed for sustainability performance by EcoVadis within the 12 months preceding the medal award date.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, December 15, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By market close, the stock was trading at HKD 46.88, with the share price remaining at relatively elevated levels throughout the session, representing a gain of 4.55%, indicating a positive market response.According to market commentary, the strong performance on the day reflected both investor focus on the Company’s newly articulated medium- to long-term strategy and confidence signals released earlier by Directors and substantial shareholder. Previously, the Company also announced that certain Directors and a substantial shareholder have increased their shareholdings in the Company. On December 12, 2025, Mr. Wei Fu, Non-executive Director, Honorary Chairman of the Board and a substantial shareholder of the Company; Mr. Yifang Wu, Executive Director and Chairman of the Board; Mr. Rogers Yongqing Luo, Executive Director and Chief Executive Officer; and Mr. Ian Ying Woo, Executive Director, President and Chief Financial Officer, collectively acquired 846,659 ordinary shares of the Company through open-market transactions, for a total consideration exceeding HK$38 million, representing an average price of approximately HK$45.01 per Share. In addition, the Company has been informed that CBC Group, a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements. The relevant actions are seen as a clear indication of Directors and substantial shareholders' positive stance on the company's long-term development prospects.The Company's 2030 strategy sets out a dual-engine approach to deliver predictable near-term growth and value creation through commercialization of existing assets, business development partnerships, and in-house R&D milestones, while driving long-term growth and value creation through in-house R&D and discovery, as well as global commercial expansion. Everest Medicines will continue to strengthen its leadership in core therapeutic areas, advance the development and commercialization of innovative therapies, and build a globally competitive biopharmaceutical company with sustainable growth.Everest Medicines focuses on renal, autoimmune, critical care, cardiovascular, and ophthalmic disease area, advancing its pipeline through a combination of in-licensed innovative assets and in-house R&D. By 2030, the Company aims to build a high-value commercial product portfolio while selectively expanding into additional valuable therapeutic areas with blockbuster potential.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle. By 2030, Everest Medicines targets annual revenue exceeding RMB 15 billion, including approximately RMB 9 billion from its existing pipeline and RMB 6 billion from newly in-licensed assets, while also exploring potential out-licensing opportunities. Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafter. Over the same period, the number of commercial products is expected to exceed 20, including NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep.To support its international growth, Everest Medicines is advancing a global strategy focused on strengthening regulatory and clinical development capabilities, while progressively building commercial infrastructure across Europe, the United States, and emerging markets. By 2030, the Company aims to drive growth through a combination of overseas out-licensing and direct commercialization, accelerating its global expansion.Notably, as a major shareholder of NovaBridge Biosciences, holding approximately 16% of its issued share capital, the Company will collaborate with NovaBridge Biosciences to identify high-quality assets and enhance global R&D and commercialization capabilities through complementary strengths and resources."The 2030 Strategy reflects Everest Medicines' clear vision for commercialization, R&D, and global expansion, and reinforces the Company's ability to deliver sustainable value. Since its founding in 2017, the Company has built a strong foundation through in-licensing innovative assets, completing its IPO, and executing a dual-engine strategy focused on high-potential therapeutic areas and strong commercialization and R&D capabilities," said Mr. Wei Fu, Honorary Chairman of the Board of Everest Medicines and CEO of CBC Group. "CBC Group will continue to leverage its global resources and ecosystem to support the Company's growth, spanning pipeline advancement, platform building, and organizational expansion. The recent share purchases by the Directors and CBC Group's announced intention to increase its shareholding further demonstrate strong confidence in Everest Medicines' long-term prospects.""The 2030 Strategy marks a key milestone for Everest Medicines, guiding growth through BD partnerships and in-house R&D to build a larger commercial portfolio and pursue new high-potential blockbuster opportunities. Leveraging its BD capabilities and the CBC ecosystem, the Company plans to add three-to-five late-stage, high-value assets annually, aiming for peak sales within three years of reimbursement, with more than 20 new assets expected to contribute around RMB 6 billion by 2030 and RMB 30 billion by 2035. Our strong balance sheet and cash flow from commercial activities will support the implementation of our strategic initiatives." said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "We will also continue to advance our in-house R&D platforms and, through our collaboration with Hasten, strengthen the late-stage pipeline and market reach.""Everest has established a scalable commercialization platform integrating medical, access, marketing, and sales capabilities," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As a chronic disease therapy, NEFECON® generated over RMB 1 billion in sales during the first three quarters of its first full year following commercial launch, validating our commercial effectiveness. Building on this success, we will extend our commercial model and expertise from renal and anti-infective therapies to additional therapeutic areas, while advancing our in vivo mRNA CAR-T and mRNA tumor vaccine platforms, addressing unmet medical needs in China and globally."Overall, the release of Everest Medicines' 2030 strategy not only sets out a systematic roadmap for future business development but also, through proactive share purchases by Directors and substantial shareholder, reflects aligned internal and external confidence in the Company's long-term prospects. Looking ahead, guided by its dual-engine strategy, Everest Medicines aims to strengthen its position in core therapeutic areas and innovative drug R&D, while building a globally competitive biopharmaceutical company with sustainable growth. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2025年12月16日 - (亚太商讯 via SeaPRwire.com) - 全球创新药估值修复与18A赛道稀缺标的争夺白热化的背景下，青岛国资深度背书的华芢生物-B（02396.HK）正式启动港股招股，以"港股PDGF第一股"的独特定位，成为年末国际配售市场的核心聚焦点。公司拟全球发售1764.88万股股份，其中国际配售占比90%（1588.38万股），香港公开发售占比10%（176.50万股），招股期至12月17日，最高发售价51.00港元，预计12月22日于港股主板挂牌。在同期六支新股并行、资金面分散的市场环境下，华芢生物凭借糖足管线的全球稀缺性、难以复制的技术壁垒、清晰的商业化路径及充足的现金流储备，精准契合全球长线机构对"确定性成长+高壁垒资产"的配置逻辑，而其核心糖足管线Pro-101-2一旦实现商业化，将成为全球范围内屈指可数的PDGF稀缺资产，开启千亿级创面愈合市场的价值重估。糖足特效药的"全球存在"与"中国缺席"：不是无药，是"用不上"糖尿病足作为糖尿病最致命的慢性并发症，正以庞大的患者基数与严峻的治疗现状，催生千亿级刚性医疗需求。根据世界卫生组织定义，糖尿病足是由神经病变和血管缺血引发的足部溃疡、感染甚至组织坏死，严重时需截肢保命，其治疗复杂且昂贵。据招股书披露，我国糖尿病患者已达1.4亿，其中糖足患病人数已突破840万，随着老龄化加速与糖尿病年轻化趋势加剧，这一数字仍在持续攀升。更令人揪心的是，糖足的致死致残率居高不下，尤其是截肢患者年死亡率更是达到22%，远超部分癌症，而传统疗法的局限性让这一困境雪上加霜。当前临床治疗仍停留在"清创+抗生素+基础护理"的传统模式，无法解决血管神经病变导致的慢性创面修复障碍，愈合率长期低于50%，给医保基金带来沉重负担。更严峻的是，全球范围内PDGF药物领域已沉寂27年——自1997年首款PDGF药物Regranex获FDA批准后，全球再无第二款同类产品上市，其15g规格售价高达1700美元，且未进入中国市场，国内患者难以企及。而国内市场长期处于国产PDGF药物"零获批"状态，临床需求与供给空白形成鲜明对比。而华芢生物核心糖足管线Pro-101-2作为已进入II期临床阶段的PDGF药物，其"血管新生-组织修复"双效机制可从根源上解决慢性创面愈合难题，每年为医保基金节约超亿元支出，完美契合医保提质控费的核心诉求，具备强大的市场渗透潜力。弗若斯特沙利文数据显示，2033年国内仅糖足市场规模将达485亿元，而整个伤口愈合市场将突破1180亿元，这片千亿蓝海正等待真正的破局者出现。技术护城河：13年积淀铸就全球稀缺竞争力PDGF药物并非普通企业可轻易涉足的领域，其背后是长达数十年的研发积淀、工艺突破与人才积累，从量变到质变的壁垒让竞争对手望尘莫及，而华芢生物历经13年深耕，已构建起"技术+工艺+专利"的三重护城河，成为全球PDGF领域的稀缺玩家。PDGF作为血小板损伤后分泌的强效生长因子，通过激活细胞信号通路促进成纤维细胞增殖与肉芽生长，是慢性创面愈合的"黄金钥匙"，但其分子结构复杂、稳定性差、生产工艺严苛，成为全球药企的研发禁区。华芢生物通过基因序列优化，剔除了5个易裂解氨基酸，显著提升了药物在人体内的稳定性与活性；生产端，公司采用毕赤酵母表达系统，相较于酿酒酵母，活性提升75倍，不仅解决了产能受限问题，更实现单位生产成本的大幅下探，打破了海外竞品的天价垄断，让国内患者"用得上、用得起"保肢药物。临床数据充分验证了技术突破的价值。Pro-101-2的I期临床结果显示其安全耐受性优良，无严重不良事件及死亡病例报告，而其针对中重度糖足的治疗优势尤为突出——可覆盖Wagner1-3级患者，既能促进慢性创面愈合，更能阻止轻症向重症恶化，填补了国内中重度糖足治疗的空白。该管线有望于2030年实现上市，成为国内首款糖足治疗PDGF药物。专利布局方面，公司已构建54项已授权及待批专利矩阵，从分子序列、表达系统到制剂工艺、适应症拓展形成全链条保护，为竞争对手设置了难以突破的知识产权屏障。这种"技术+工艺+专利"的三重壁垒，让PDGF赛道形成近乎独家的竞争格局，而华芢生物作为唯一持续推进的企业，其稀缺性在全球创新药领域尤为珍贵。商业化确定性：资金-研发-商业化正向闭环，铸就机构青睐的18A稀缺标的对国际配售机构而言，清晰的商业化路径与充足的资金储备是规避研发型企业风险的核心，而华芢生物凭借"糖足+烧烫伤"双管线协同以及多重风险对冲优势，成为"风险可量化、成长可预期"的稀缺配置标的。多重风险对冲优势进一步强化了机构配置信心。青岛国资作为核心股东，不仅为公司提供资金支持，更使其成为地方政府重点扶持的生物医药名片，在研发资源对接、政策协同、产业化等方面具备显著优势。其联席保荐人中信证券2025年在18A赛道表现亮眼，保荐的7个项目均实现首日未破发，其中映恩生物、劲方医药等首日涨幅超100%，12月10日挂牌的宝济药业更是录得3526.34倍公开发售认购、暗盘一度暴涨超115%的佳绩，亦强化市场信心。更值得关注的是，公司已完成2000L规模商业化生产工艺，具备从临床到商业化的完整技术衔接能力，且PDGF药物通过缩短住院时间、降低截肢率，与DRG/DIP支付改革方向高度契合，商业化路径明确。此外，公司具备"小流通盘+纯正18A属性"优势，未来有望快速进入港股通，参考历史数据，港股通纳入后南向资金的持续配置将为股价提供显著流动性溢价，契合机构对资产流动性的核心要求。在全球创新药估值修复、18A赛道稀缺标的争夺加剧的背景下，华芢生物正站在"国产PDGF第一股"的关键节点。其核心糖足管线Pro-101-2一旦实现商业化，将成为全球范围内屈指可数的PDGF稀缺资产，打破27年的技术垄断与市场空白，切入千亿级刚需市场；而烧烫伤管线的率先落地将奠定现金流基础，打开长期成长空间。对国际配售机构而言，这家兼具"国资护航+技术壁垒+刚需属性+优质保荐+现金流闭环"的18A稀缺标的，不仅具备清晰的临床推进路径与商业化前景，更有望凭借港股通预期与赛道稀缺性实现价值重估。华芢生物正迎来临床价值与资本市场价值的双重兑现期，为全球长线机构提供了年末布局"确定性成长+高壁垒资产"的优选机遇，而其作为全球PDGF领域稀缺玩家的价值，也将在商业化进程中持续凸显。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
深圳, 2025年12月16日 - (亚太商讯 via SeaPRwire.com) - 12月15日，康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）拥有相关许可权利的创新口服JAK1抑制剂povorcitinib（拟定中文通用名：磷酸泊沃昔替尼片）（"povorcitinib"或"产品"）已获中国国家药品监督管理局（"NMPA"）药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。此次认定有望加快该产品的研发与审评进程。Povorcitinib是一种选择性口服小分子JAK1抑制剂，在区域内特定国家/地区拥有物质和用途专利。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎（HS）和结节性痒疹的3期临床试验。另外，治疗哮喘的2期临床试验也在进行中。2023年3月，Incyte公布povorcitinib达到了非节段型白癜风的全球多中心2b期临床研究的主要终点。结果显示：治疗24周，与安慰剂相比，接受每日一次povorcitinib治疗的患者的全身皮损显著复色。随后该2b期试验的扩展期结果表明，长期使用povorcitinib可进一步促进全身和面部的复色，且耐受性良好[1]。2025年8月，德镁医药获NMPA签发的药物临床试验批准通知书，同意开展povorcitinib用于治疗非节段型白癜风等适应症的临床试验。德镁医药已启动产品在中国的临床开发工作，并考虑择机在中国推动其治疗HS和结节性痒疹等皮肤相关疾病的临床开发。白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国约有1030万人患有白癜风，其中约820万人患有非节段型白癜风[2]。目前白癜风疗法选择有限且难以治疗，特别是对于累及面积大的白癜风患者。若于中国获批，povorcitinib有望为非节段型白癜风患者提供差异化的治疗选择。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。若于中国获批上市，该产品将有望与德镁医药在售创新药益路取（替瑞奇珠单抗注射液）、在售独家药喜辽妥（多磺酸粘多糖乳膏）及正处于新药上市申请（NDA）阶段的创新药磷酸芦可替尼乳膏形成协同，推动产品快速实现临床和商业价值，惠及更多皮肤疾病患者。此外，该产品还将与外用磷酸芦可替尼乳膏共同为白癜风患者提供差异化、全面的治疗选择。康哲药业于2024年3月31日，通过德镁医药的附属公司与Incyte就povorcitinib订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国（"区域"）研究、开发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将povorcitinib除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 产品非节段型白癜风适应症的全球多中心2b期临床结果可在Incyte官网查询：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. 数据来自灼识咨询报告康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
